Capricor Therapeutics (CAPR) Tops Q4 EPS by 3c

Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $9.59 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• MIND Technology (MIND) Misses Q1 EPS by 5c